RPS16-1 Antibody

What is RPS16 and why is it significant in cellular research?

RPS16 (ribosomal protein S16) is a critical component of the 40S ribosomal subunit and belongs to the S9P family of ribosomal proteins. It is primarily located in the cytoplasm and can be acetylated. RPS16 plays essential roles in rRNA processing, translational elongation, initiation, and termination through its RNA binding activity . Recent research has identified RPS16 as significant in oncological studies, particularly in hepatocellular carcinoma (HCC), breast cancer, and gliomas, where it functions through pathways including PI3K/AKT/Snail and interaction with deubiquitinating enzymes like USP1 . This positions RPS16 as a valuable research target for understanding both fundamental translation mechanisms and pathological processes in cancer.

What applications are validated for RPS16 antibodies in research contexts?

RPS16 antibodies have been extensively validated across multiple experimental applications:

These applications have been documented in peer-reviewed publications, with at least two publications citing WB applications and one for IHC . For optimal results, researchers should consider titrating the reagent in each specific testing system as sensitivity may vary depending on the experimental conditions and sample types.

How does RPS16 antibody specificity compare across species?

The specificity profile of RPS16 antibodies shows varying degrees of cross-reactivity:

This cross-reactivity profile is particularly valuable for comparative studies across model organisms. When designing experiments involving multiple species, researchers should validate the antibody's performance in their specific experimental context through appropriate controls, as reactivity strength may vary between species despite conservation of the protein sequence .

What are the optimal storage conditions for maintaining RPS16 antibody activity?

To maintain optimal RPS16 antibody activity over time, adhere to these evidence-based storage recommendations:

• Store at -20°C for long-term preservation

• The antibody remains stable for one year after shipment when properly stored

• For antibodies in liquid form, use PBS buffer with 0.02% sodium azide and 50% glycerol at pH 7.3

• Aliquoting is generally unnecessary for -20°C storage (specifically noted for 15603-1-AP)

• For lyophilized formulations (like PRSI27-879), reconstitute in 100 μL distilled water to achieve a final concentration of 1 mg/mL

• After reconstitution, aliquot and store at -20°C or below

• Avoid multiple freeze-thaw cycles which can significantly reduce antibody performance

These guidelines ensure maintained immunoreactivity throughout the shelf life of the antibody.

What antigen retrieval methods are most effective for RPS16 detection in FFPE tissue sections?

For optimal RPS16 detection in formalin-fixed paraffin-embedded (FFPE) tissue sections, the following antigen retrieval protocols have been empirically validated:

• Primary recommendation: Tris-EDTA (TE) buffer at pH 9.0

• Alternative approach: Citrate buffer at pH 6.0 has also shown efficacy

The choice between these methods may depend on tissue type and fixation conditions. For human breast cancer tissue specifically, TE buffer at pH 9.0 has demonstrated superior results in revealing RPS16 epitopes while maintaining tissue morphology. Researchers should optimize incubation times based on section thickness and fixation duration, typically ranging from 15-30 minutes at 95-100°C.

How should co-immunoprecipitation be performed to study RPS16 protein interactions?

For investigating RPS16 protein interactions, the following co-immunoprecipitation (Co-IP) methodology has been successfully employed:

• Antibody coupling preparation:

  • Incubate dynabeads with specified antibodies for 16-24 hours

  • Use an Antibody Coupling Kit (e.g., #14311D, Invitrogen)

• Sample processing:

  • Extract cell lysates from target cells (e.g., HCC cell lines)

  • Incubate the antibody-coupled dynabeads with cell lysates for 1-2 hours

  • Form protein-dynabeads-antibody complexes

• Complex dissociation and analysis:

  • Mix complexes with blue SDS-binding buffer

  • Incubate in 70°C water bath for 10 minutes

  • Separate interacting proteins by centrifugation at 13,000 rpm for 2 minutes

  • Collect supernatant for downstream analysis including biological mass spectrometry and western blotting

This protocol has successfully demonstrated the interaction between RPS16 and USP1, revealing important regulatory mechanisms in HCC cells. When adapting this protocol, researchers should include appropriate controls, such as IgG antibodies, to distinguish specific from non-specific interactions.

How does the USP1-RPS16 interaction affect cancer cell metabolism and proliferation?

The USP1-RPS16 interaction represents a critical regulatory axis in cancer cell metabolism and proliferation, particularly in hepatocellular carcinoma (HCC). Research has revealed:

• Mechanistic basis: USP1 (ubiquitin-specific peptidase 1) directly interacts with RPS16, specifically through its C-terminal domain (401-785 amino acids). This interaction deubiquitinates RPS16, preventing its proteasomal degradation.

• Molecular consequences:

  • USP1 depletion increases K48-linked ubiquitinated-RPS16, promoting proteasome-dependent degradation

  • Overexpression of wild-type USP1 (but not the catalytically inactive C90A mutant) reduces K48-linked ubiquitinated RPS16, stabilizing the protein

  • The stabilized RPS16 regulates Twist1 and Snail expression, promoting epithelial-mesenchymal transition

• Cellular outcomes:

  • Enhanced cell proliferation

  • Increased metastatic potential

  • Resistance to apoptosis

• Clinical correlation:

  • High expression of both USP1 and RPS16 in liver tissue correlates with poor survival in HCC patients

  • The positive correlation between USP1 and RPS16 expression suggests coordinated regulatory mechanisms in tumor tissues

These findings highlight the potential of targeting the USP1-RPS16 pathway as a therapeutic strategy for aggressive HCC.

What methodologies are most effective for studying RPS16 roles in translational control during cellular stress?

To effectively investigate RPS16 functions in translational control during cellular stress, researchers should employ a multi-modal approach:

• Polysome profiling:

  • Fractionate cytoplasmic lysates on sucrose gradients

  • Monitor RPS16 distribution across non-translating and actively translating fractions before and during stress

  • Compare with other ribosomal proteins and translation factors

• Ribosome footprinting (Ribo-seq):

  • Generate libraries of ribosome-protected mRNA fragments

  • Analyze with next-generation sequencing to identify transcripts differentially regulated by RPS16

  • Map precise ribosome positions to identify potential regulatory regions

• SILAC-based proteomics:

  • Metabolically label cells with heavy/light amino acids

  • Compare proteome changes in RPS16 knockdown/overexpression conditions

  • Identify specific pathways affected by RPS16-dependent translation

• RPS16 mutagenesis:

  • Generate phosphomimetic or phospho-deficient mutants of known modification sites

  • Create domain-specific mutants to disrupt specific interactions

  • Assess effects on stress granule formation, translation initiation complex assembly, and substrate specificity

These approaches, combined with gene editing technologies like CRISPR-Cas9 to modulate RPS16 expression, provide comprehensive insights into its specialized roles beyond core ribosomal functions.

How can molecular dynamics simulation be applied to study RPS16 interactions with regulatory proteins?

Molecular dynamics simulation provides powerful insights into the structural basis of RPS16 interactions with regulatory proteins like USP1. An effective implementation approach includes:

• Initial model preparation:

  • Generate 3D structures of RPS16 and interaction partners based on crystallographic data or homology modeling

  • Apply appropriate force fields calibrated for protein-protein interactions

  • Solvate the system in explicit water molecules with physiological ion concentrations

• Simulation parameters:

  • Run extended simulations (minimum 50 nanoseconds) to allow conformational sampling

  • Maintain constant temperature (310K) and pressure (1 atm) to mimic physiological conditions

  • Apply periodic boundary conditions to avoid edge effects

• Analysis of interaction interfaces:

  • Calculate binding free energies using methods like MM-PBSA or FEP

  • Identify key residues mediating interactions through hydrogen bonds, salt bridges, or hydrophobic contacts

  • Map interaction hotspots to guide mutagenesis experiments

• Validation strategies:

  • Compare simulation predictions with experimental data from co-IP or cross-linking studies

  • Test predicted critical residues through site-directed mutagenesis

  • Assess biological significance through functional assays

This approach has successfully identified three-dimensional binding conformations of the USP1-RPS16 complex, providing structural insights that could guide the development of inhibitors targeting this interaction.

How can researchers address non-specific binding when using RPS16 antibodies?

Non-specific binding is a common challenge when working with antibodies against highly conserved ribosomal proteins like RPS16. Implement these evidence-based strategies to minimize background and enhance specificity:

• Blocking optimization:

  • Test different blocking agents (BSA, non-fat milk, normal serum)

  • For RPS16 antibodies, BSA (0.1-5%) has shown better results in reducing background

  • Extend blocking time to 2 hours at room temperature for challenging samples

• Antibody dilution refinement:

  • Perform titration experiments across the recommended dilution range

  • For WB: Test gradients between 1:500-1:1000

  • For IHC: Start with 1:100 and adjust based on signal-to-noise ratio

  • For IF/ICC: Test multiple dilutions between 1:10-1:100

• Sample-specific controls:

  • Include RPS16 knockdown/knockout samples as negative controls

  • Use recombinant RPS16 protein for antibody pre-absorption to confirm specificity

  • Compare patterns with multiple antibodies targeting different RPS16 epitopes

• Buffer and wash optimization:

  • Increase Tween-20 concentration (0.1-0.3%) in wash buffers

  • Add low concentrations of SDS (0.01-0.05%) to reduce hydrophobic interactions

  • Increase number and duration of washing steps

These strategies significantly improve signal specificity while preserving detection sensitivity for valid RPS16 signals.

What are the critical considerations when interpreting RPS16 expression data across different cancer types?

When interpreting RPS16 expression data across cancer types, researchers should account for these critical factors:

• Context-dependent roles:

  • RPS16 functions as an oncoprotein in breast cancer and gliomas through mechanisms including doxorubicin resistance and PI3K/AKT/Snail pathway activation

  • In HCC, its oncogenic effects depend on USP1-mediated stabilization and subsequent regulation of Twist1 and Snail

  • These diverse mechanisms suggest tissue-specific regulatory networks that must be considered when comparing across cancers

• Subcellular localization variations:

  • While primarily cytoplasmic, RPS16 localization patterns may vary with malignancy

  • Correlation of expression with subcellular distribution provides more meaningful insights than total expression alone

  • Use cellular fractionation combined with immunoblotting or high-resolution imaging to assess compartment-specific changes

• Post-translational modification status:

  • RPS16 can be acetylated, affecting its function and interactions

  • Ubiquitination status (particularly K48-linked chains) impacts stability and abundance

  • Use modification-specific antibodies or mass spectrometry to determine modification profiles alongside expression data

• Integration with pathway data:

  • Correlate RPS16 expression with known interactors (e.g., USP1)

  • Assess relationship to downstream effectors (Twist1, Snail)

  • Consider ribosomal vs. extra-ribosomal functions in interpretation

This comprehensive analytical approach prevents misinterpretation of expression data and helps distinguish driver from passenger alterations in cancer.

How should discrepancies between RPS16 protein levels and mRNA expression be investigated?

Discrepancies between RPS16 protein and mRNA levels often reflect complex post-transcriptional regulatory mechanisms. A systematic investigation should include:

• Protein stability assessment:

  • Perform cycloheximide chase assays to determine RPS16 protein half-life

  • Compare protein stability in different cellular contexts or conditions

  • Use proteasome inhibitors (e.g., Bortezomib/BTZ) to assess contribution of proteasome-dependent degradation

• Ubiquitination analysis:

  • Conduct immunoprecipitation with RPS16 antibodies followed by ubiquitin immunoblotting

  • Specifically examine K48-linked ubiquitination, which targets proteins for proteasomal degradation

  • Compare ubiquitination patterns across experimental conditions using chain-specific antibodies

• Deubiquitinating enzyme activity:

  • Investigate the role of DUBs like USP1 using both genetic (RNAi) and pharmacological (ML323) approaches

  • Perform co-IP experiments to identify novel DUBs that might regulate RPS16

  • Conduct in vitro deubiquitination assays with purified components to confirm direct effects

• Translational efficiency evaluation:

  • Use polysome profiling to assess RPS16 mRNA association with actively translating ribosomes

  • Employ ribosome profiling to examine translation initiation efficiency

  • Analyze potential regulatory elements in 5' and 3' UTRs that might influence translation

• Statistical analysis:

  • Apply appropriate statistical methods (t-tests, ANOVA) to quantify significance of observed differences

  • Use Pearson correlation analysis to assess relationships between protein and mRNA levels across samples

  • Consider non-parametric tests when data distribution is non-normal

This methodical approach can reveal complex regulatory mechanisms explaining observed discrepancies and potentially identify novel therapeutic targets in diseases involving RPS16 dysregulation.

What emerging technologies might enhance the study of RPS16 post-translational modifications?

Several cutting-edge technologies are poised to revolutionize our understanding of RPS16 post-translational modifications (PTMs):

• Proximity-dependent biotinylation (BioID/TurboID):

  • Fusion of biotin ligase to RPS16 enables identification of proximal proteins

  • Temporal control allows mapping of interaction changes during stress or disease progression

  • When combined with PTM-specific antibodies, can reveal modifiers and readers of RPS16 modifications

• Cross-linking mass spectrometry (XL-MS):

  • Maps precise interaction interfaces between RPS16 and regulatory proteins

  • Identifies structural changes induced by specific PTMs

  • Reveals conformational effects of modifications on ribosome structure

• CRISPR base editing for endogenous modification:

  • Precise modification of RPS16 PTM sites without disrupting protein expression

  • Creation of acetylation-mimetic or phosphomimetic mutations at endogenous loci

  • Assessment of modification effects in physiologically relevant contexts

• Nanobodies and intrabodies:

  • Development of modification-specific nanobodies for live-cell imaging of RPS16 PTMs

  • Monitoring dynamic changes in modification status during cellular responses

  • Potential therapeutic applications targeting specific modified forms

These technologies, when applied systematically, will provide unprecedented insights into how PTMs regulate RPS16 function in both normal and pathological states.

How might targeting the USP1-RPS16 axis translate into novel cancer therapeutics?

The USP1-RPS16 regulatory axis presents several promising therapeutic opportunities:

• Small molecule inhibitor development:

  • Structure-based design of compounds disrupting the USP1-RPS16 interaction interface

  • Allosteric modulators affecting USP1 catalytic activity toward RPS16

  • Selective degraders (PROTACs) targeting the complex for destruction

• Combination therapy strategies:

  • Synergistic pairing with proteasome inhibitors to enhance RPS16 degradation

  • Sequential targeting of upstream regulators and downstream effectors (Twist1, Snail)

  • Integration with conventional chemotherapeutics to overcome resistance mechanisms

• Biomarker development:

  • USP1 and RPS16 co-expression as prognostic indicators

  • Monitoring of target engagement using proximal biomarkers

  • Patient stratification based on pathway activation status

• Delivery innovations:

  • Tumor-specific targeting using nanoparticles or antibody-drug conjugates

  • Hepatocyte-directed delivery systems for HCC applications

  • Combinatorial approaches targeting multiple nodes in the regulatory network

Clinical translation will require careful assessment of potential off-target effects, particularly given RPS16's fundamental role in protein synthesis, necessitating the development of cancer-selective targeting strategies.

What computational approaches can predict functional consequences of RPS16 mutations in human disease?

Advanced computational approaches offer powerful frameworks for predicting the functional impact of RPS16 mutations:

• Integrative structural modeling:

  • Incorporation of cryo-EM data of ribosomal complexes

  • Molecular dynamics simulations of mutant effects on ribosome assembly and function

  • Prediction of altered interaction networks within the translational machinery

• Systems biology frameworks:

  • Constraint-based modeling of translational output with mutant RPS16

  • Network propagation algorithms to predict pathway-level consequences

  • Integration with multi-omics data to contextualize predictions

• Machine learning approaches:

  • Training on known ribosomopathy mutations to predict novel variant effects

  • Feature extraction from evolutionary conservation, structural context, and biochemical properties

  • Classification of variants into functional categories based on predicted impact severity

• Clinical data integration:

  • Correlation of computational predictions with patient outcomes

  • Natural language processing of case reports and literature

  • Bayesian frameworks incorporating population-level data and individual characteristics

These approaches, when combined, can prioritize variants for functional validation and provide mechanistic hypotheses for clinical observations, potentially guiding personalized therapeutic strategies for patients with RPS16 mutations.

What are the key considerations for designing experiments investigating RPS16 in different model systems?

When designing experiments to investigate RPS16 across model systems, researchers should consider:

• System-specific expression patterns:

  • Different model organisms show varying levels of RPS16 base expression

  • Tissue-specific expression patterns may influence experimental outcomes

  • Developmental timing of expression can affect phenotypic consequences of manipulation

• Knockdown/knockout strategies:

  • Complete knockout may be lethal due to RPS16's essential role in translation

  • Conditional or inducible systems often provide more useful insights

  • Partial knockdown (30-70%) typically offers better balance between viability and phenotype

• Appropriate controls:

  • Include other ribosomal proteins as specificity controls

  • Rescue experiments with wild-type RPS16 to confirm specificity

  • Time-course analyses to distinguish primary from secondary effects

• Cross-species considerations:

  • Antibody cross-reactivity varies between species despite protein conservation

  • Different species may employ distinct regulatory mechanisms

  • Evolutionary conservation analysis can guide functional domain studies

These considerations enable robust experimental design that maximizes translational relevance while accounting for system-specific variables.

What standardized protocols should researchers adopt for reproducible RPS16 research?

To enhance reproducibility in RPS16 research, the following standardized protocols are recommended:

• Antibody validation:

  • Verify specificity using siRNA/CRISPR knockdown controls

  • Document lot number and dilution optimization for each application

  • Include multiple antibodies targeting different epitopes when possible

• Expression analysis:

  • Normalize RPS16 protein levels to total protein rather than single housekeeping genes

  • Use digital PCR or multiple reference genes for mRNA quantification

  • Document cell confluence and passage number for cultured cell experiments

• Interaction studies:

  • Follow established co-IP protocols with standardized buffer compositions

  • Include multiple controls (IgG, reverse IP, competitive binding)

  • Quantify interaction strength using calibrated standards

• Statistical analysis:

  • Perform minimum three independent biological replicates

  • Apply appropriate statistical tests based on data distribution

  • Report effect sizes alongside p-values

  • Use standardized reporting formats (e.g., ARRIVE guidelines for animal studies)

Adopting these protocols significantly enhances data reliability and facilitates meta-analysis across studies, accelerating collective understanding of RPS16 biology.

How should researchers prioritize RPS16 research questions to maximize translational impact?

To maximize translational impact of RPS16 research, prioritize questions according to this framework:

• Mechanism-focused investigations:

  • Characterize tissue-specific regulatory mechanisms controlling RPS16 levels

  • Delineate extra-ribosomal functions distinct from core translation

  • Map the complete interactome in normal versus disease states

• Disease-relevance hierarchies:

  • Focus on cancers with established RPS16 dysregulation (HCC, breast cancer, gliomas)

  • Investigate potential roles in diseases with ribosomal protein imbalance

  • Explore connections to stress response pathways relevant to multiple pathologies

• Therapeutic potential assessment:

  • Prioritize studies of druggable regulatory mechanisms (e.g., USP1-RPS16 interaction)

  • Develop biomarkers for patient stratification based on pathway activation

  • Evaluate synergistic combinations with existing therapies

• Technology development:

  • Create tools enabling temporal and spatial control of RPS16 function

  • Develop selective methods to distinguish ribosomal from extra-ribosomal roles

  • Generate resources (antibodies, cell lines, animal models) for community use